Kura Oncology (KURA) Downgraded by BidaskClub to Sell
Kura Oncology (NASDAQ:KURA) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Thursday.
Several other analysts also recently commented on KURA. Leerink Swann reissued an “outperform” rating and set a $18.00 price objective (up from $16.00) on shares of Kura Oncology in a research report on Thursday, August 10th. ValuEngine downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research cut shares of Kura Oncology from a “buy” rating to a “hold” rating and set a $7.25 target price on the stock. in a research note on Wednesday, August 23rd. Oppenheimer set a $18.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a research note on Thursday, November 16th. Finally, Citigroup upped their target price on shares of Kura Oncology from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $17.60.
Kura Oncology (NASDAQ:KURA) remained flat at $$14.15 during trading hours on Thursday. The stock had a trading volume of 422,582 shares, compared to its average volume of 289,422. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 13.48. Kura Oncology has a 1-year low of $5.20 and a 1-year high of $17.50.
Several large investors have recently modified their holdings of KURA. California State Teachers Retirement System raised its stake in Kura Oncology by 24.5% during the 3rd quarter. California State Teachers Retirement System now owns 31,500 shares of the company’s stock worth $471,000 after acquiring an additional 6,200 shares during the period. Nationwide Fund Advisors raised its stake in Kura Oncology by 66.2% during the 2nd quarter. Nationwide Fund Advisors now owns 25,758 shares of the company’s stock worth $240,000 after acquiring an additional 10,258 shares during the period. State of Wisconsin Investment Board purchased a new stake in Kura Oncology during the 2nd quarter valued at approximately $102,000. Rhumbline Advisers purchased a new stake in Kura Oncology during the 2nd quarter valued at approximately $131,000. Finally, Schwab Charles Investment Management Inc. grew its holdings in Kura Oncology by 61.3% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 39,200 shares of the company’s stock valued at $587,000 after buying an additional 14,900 shares in the last quarter. Hedge funds and other institutional investors own 64.26% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/07/kura-oncology-kura-downgraded-by-bidaskclub-to-sell.html.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.